These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38638312)

  • 21. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates.
    Inshasi JS; Alfahad S; Alsaadi T; Hassan A; Zein T; Mifsud VA; Nouri SI; Shakra M; Shatila AO; Szolics M; Thakre M; Kumar A; Boshra A
    Neurol Ther; 2021 Dec; 10(2):435-454. PubMed ID: 33891277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States.
    Song Y; Wang Y; Wong SL; Yang D; Sundar M; Tundia N
    Mult Scler Relat Disord; 2023 Nov; 79():105052. PubMed ID: 37832254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
    Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
    Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS).
    Patti F; Visconti A; Capacchione A; Roy S; Trojano M;
    Ther Adv Neurol Disord; 2020; 13():1756286420922685. PubMed ID: 32587633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
    Mao Z; Álvarez-González C; Allen-Philbey K; De Trane S; Yildiz O; Campion T; Adams A; Turner BP; Marta M; Gnanapavan S; Espasandin M; Mathews J; Giovannoni G; Baker D; Schmierer K
    Mult Scler Relat Disord; 2019 Jan; 27():247-253. PubMed ID: 30419510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
    Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
    CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab for people with multiple sclerosis.
    Filippini G; Kruja J; Del Giovane C
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
    Brochet B; Solari A; Lechner-Scott J; Piehl F; Langdon D; Hupperts R; Selmaj K; Patti F; Brieva L; Maida EM; Alexandri N; Smyk A; Nolting A; Keller B; Montalban X; Kubala Havrdova E
    Mult Scler; 2023 Dec; 29(14):1808-1818. PubMed ID: 37978852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    Zanetta C; Rocca MA; Meani A; Martinelli V; Ferrè L; Moiola L; Filippi M
    J Neurol; 2023 Jul; 270(7):3553-3564. PubMed ID: 37027018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED
    CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
    Meuth SG; Ruck T; Aktas O; Hartung HP
    Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
    Negrotto L; Iut VC; Etchepare A; D'Eramo M; Grinspan A; Assefi A
    Mult Scler Relat Disord; 2022 Dec; 68():104403. PubMed ID: 36544327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B; Guerreiro R; Costa J; Miguel LS
    J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
    [No Abstract]   [Full Text] [Related]  

  • 35. Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Cortese R; Testa G; Assogna F; De Stefano N
    CNS Drugs; 2024 Apr; 38(4):267-279. PubMed ID: 38489020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.
    Butzkueven H; Moore N; Aydemir A; Sõnajalg J; Bezemer I; Korhonen P; Sabidó M;
    Curr Med Res Opin; 2022 Jul; 38(7):1167-1176. PubMed ID: 35357268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal.
    Santos M; Sequeira J; Abreu P; Guerreiro R; Santos M; Ferreira J; Brum M; Ladeira F; Leitão L; Dias R; Sá MJ; Salgado V; Capela C; de Sá J
    Clin Neuropharmacol; 2023 May-Jun 01; 46(3):105-111. PubMed ID: 37191564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
    Meca-Lallana JE; Prieto González JM; Caminero Rodríguez AB; Olascoaga Urtaza J; Alonso AM; Durán Ferreras E; Espinosa R; Dotor J; Romera M; Ares Luque A; Pérez Ruiz D; Calles C; Hernández MA; Hervás García M; Mendoza Rodríguez A; Berdei Montero Y; Téllez N; Herrera Varó N; Sotoca J; Presas-Rodríguez S; Querol Gutierrez LA; Hervás Pujol M; Batlle Nadal J; Martín Ozaeta G; Gubieras Lillo L; Martínez Yélamos S; Ramió-Torrentà L; Mallada Frechin J; Belenguer Benavides A; Gascón-Giménez F; Casanova B; Landete Pascual L; Berenguer L; Navarro L; Gómez Gutierrez M; Durán C; Rodríguez Regal A; Álvarez E; García-Estévez DA; López Real AM; Llaneza González MA; Marzo Sola ME; Sánchez-Menoyo JL; Oterino A; Villaverde González R; Castillo-Triviño T; Álvarez de Arcaya A; Llarena C
    Neurol Ther; 2023 Dec; 12(6):2177-2193. PubMed ID: 37861931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
    Gonzalez-Lorenzo M; Ridley B; Minozzi S; Del Giovane C; Peryer G; Piggott T; Foschi M; Filippini G; Tramacere I; Baldin E; Nonino F
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011381. PubMed ID: 38174776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
    Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.